2-[3-[2-[[Benzyl(methoxycarbonyl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxyphenyl]acetic acid | 1347747-19-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[3-[2-[[Benzyl(methoxycarbonyl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxyphenyl]acetic acid
• CAS: 1347747-19-6
• 化学式: C₂₆H₂₄F₃NO₅
• 分子量: 487.475
• InChiKey: WGXIPXHUOIQNGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  ethyl 2-(2'-((benzylamino)methyl)-6-methoxy-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetate 在 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 生成 2-[3-[2-[[Benzyl(methoxycarbonyl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxyphenyl]acetic acid
  参考文献：
  名称：

  Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis

  摘要：

  Biphenylacetic acid (5) was identified through a library screen as an inhibitor of the prostaglandin D-2 receptor DP2 (CRTH2). Optimization for potency and pharmacokinetic properties led to a series of selective CRTH2 antagonists. Compounds demonstrated potency in a human DP2 binding assay and a human whole blood eosinophil shape change assay, as well as good oral bioavailability in rat and dog, and efficacy in a mouse model of allergic rhinitis following oral dosing. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.01.024

文献信息

• N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：HUTCHINSON John Howard

  公开号：US20120058123A1

  公开（公告）日：2012-03-08

  Described herein are compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD 2 receptors. Also described herein are methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本文描述了一些PGD2受体拮抗剂化合物。还描述了包括这些PGD2受体拮抗剂化合物的药物组合物和药物。此外，还描述了使用这些PGD2受体拮抗剂，单独或与其他化合物联合治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症的方法。
• US8067445B2
  申请人：——

  公开号：US8067445B2

  公开（公告）日：2011-11-29
• US8362044B2
  申请人：——

  公开号：US8362044B2

  公开（公告）日：2013-01-29
• [FR] ANTAGONISTES AMINOALKYLBIPHÉNYLE DISUBSTITUÉS PAR N,N DES RÉCEPTEURS DE LA PROSTAGLANDINE D<subinvention>20090813WO2005100298A1MERCK & CO INC [US], et al20051027AAUS2002198251A1SUNDERMANN BERND [DE], et al20021226AAUS5239084AGUERRY PHILIPPE [CH], et al19930824AAWO2006056854A1PFIZER PROD INC [US], et al20060601AAWO2006014357A1MERCK & CO INC [US], et al20060209AASee references of EP 2257524A4WO2004058164A2TULARIK INC [US]20040715
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2009099902A1

  公开（公告）日：2009-08-13

  Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
• Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis
  作者：Jill M. Scott、Christopher Baccei、Gretchen Bain、Alex Broadhead、Jilly F. Evans、Patrick Fagan、John H. Hutchinson、Christopher King、Daniel S. Lorrain、Catherine Lee、Peppi Prasit、Pat Prodanovich、Angelina Santini、Brian A. Stearns

  DOI：10.1016/j.bmcl.2011.01.024

  日期：2011.11

  Biphenylacetic acid (5) was identified through a library screen as an inhibitor of the prostaglandin D-2 receptor DP2 (CRTH2). Optimization for potency and pharmacokinetic properties led to a series of selective CRTH2 antagonists. Compounds demonstrated potency in a human DP2 binding assay and a human whole blood eosinophil shape change assay, as well as good oral bioavailability in rat and dog, and efficacy in a mouse model of allergic rhinitis following oral dosing. (C) 2011 Published by Elsevier Ltd.